Platelet serotonin transporter function after short-term paroxetine treatment in patients with panic disorder

Psychiatry Research

Volumn 176, Issue 2-3, 2010, Pages 250-253

  Kang, Eun Ho ^a   Shim, Hyun Bo ^a   Kim, Kyung Jeong ^b   Park, Joo Eon ^c   Lee, In Soo ^d   Yu, Bum Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Keyo Hospital   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Panic disorder; Paroxetine; Serotonin transporter; Serotonin uptake

Indexed keywords

PAROXETINE; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; HYPOTHESIS; MALE; NEUROTRANSMISSION; PANIC; PRIORITY JOURNAL; PROTEIN FUNCTION; SEROTONIN UPTAKE; THROMBOCYTE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRITIUM;

EID: 77949775655     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.12.007     Document Type: Article

References (32)

1. Ballenger J.C. Remission rates in patients with anxiety disorders treated with paroxetine. Journal of Clinical Psychiatry 2004, 65:1696-1707.
2. Blaya C., Salum G.A., Lima M.S., Leistner-Segal S., Manfro G.G. Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. Behavior and Brain Functions 2007, 3:41.
3. Camacho A., Dimsdale J.E. Platelets and psychiatry: lessons learned from old and new studies. Psychosomatic Medicine 2000, 62:326-336.
4. den Boer J.A., Westenberg H.G. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990, 102:85-94.
5. Eaton W.W., Kessler R.C., Wittchen H.U., Magee W.J. Panic and panic disorder in the United States. American Journal of Psychiatry 1994, 151:413-420.
6. Faludi G., Tekes K., Tóthfalusi L. Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls. Journal of Psychiatry and Neuroscience 1994, 19:109-113.
7. Goddard A.W., Charney D.S., Germine M., Woods S.W., Heninger G.R., Krystal J.H., Goodman W.K., Price L.H. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biological Psychiatry 1995, 38:74-85.
8. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959, 32:50-55.
9. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
10. Kahn R.S., van Praag H.M. Panic disorder: a biological perspective. European Neuropsychopharmacology 1992, 2:1-20.
11. Kahn R.S., Westenberg H.G. L-5-hydroxytryptophan in the treatment of anxiety disorders. Journal of Affective Disorders 1985, 8:197-200.
12. Kahn R.S., Westenberg H.G., Verhoeven W.M., Gispen-de Wied C.C., Kamerbeek W.D. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology 1987, 2:33-45.
13. Klaassen T., Klumperbeek J., Deutz N.E., van Praag H.M., Griez E. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Research 1998, 77:167-174.
14. Lesch K.P., Wolozin B.L., Murphy D.L., Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. Journal of Neurochemistry 1993, 60:2319-2322.
15. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Müller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
16. Lim Y.J., Yu B.H., Kim J.H. Korean panic disorder severity scale: construct validity by confirmatory factor analysis. Depression and Anxiety 2007, 24:95-102.
17. Lin P.Y. Meta-analysis of the association of serotonin transporter gene polymorphism with obsessive-compulsive disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:683-689.
18. Lingjaerde O. Effects of benzodiazepine receptor ligands midazolam, Ro 15-1788, and Ro 5-4863 and in combinations on platelet serotonin uptake. Pharmacopsychiatry 1986, 19:15-18.
19. Maguire K.P., Norman T.R., Apostolopoulos M., Judd F.K., Burrows G.D. Platelet [3H]paroxetine binding in panic disorder. Journal of Affective Disorders 1995, 33:117-122.
20. Maron E., Shlik J. Serotonin function in panic disorder: important, but why?. Neuropsychopharmacology 2006, 31:1-11.
21. Miller H.E., Deakin J.F., Anderson I.M. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. British Journal of Psychiatry 2000, 176:182-188.
22. Neuger J., Wistedt B., Sinner B., Aberg-Wistedt A., Stain-Malmgren R. The effect of citalopram treatment on platelet serotonin function in panic disorders. International Clinical Psychopharmacology 2000, 15:83-91.
23. Neuger J., Wistedt B., Aberg-Wistedt A., Stain-Malmgren R. Effect of citalopram treatment on relationship between platelet serotonin functions and the Karolinska scales of personality in panic patients. Journal of Clinical Psychopharmacology 2002, 22:400-405.
24. Norman T.R., Gregory M.S., Judd F.K., Burrows G.D., McIntyre I.M. Platelet serotonin uptake in panic disorder: comparison with normal controls and the effect of treatment. Australian and New Zealand journal of Psychiatry 1988, 22:390-395.
25. Nutt D.J., Fraser S. Platelet binding studies in panic disorder. Journal of Affective Disorders 1987, 12:7-11.
26. Pecknold J.C., Suranyi-Cadotte B., Chang H., Nair N.P. Serotonin uptake in panic disorder and agoraphobia. Neuropsychopharmacology 1988, 1:173-176.
27. Pollack M.H., Marzol P.C. Panic: course, complications and treatment of panic disorder. Journal of Psychopharmacology 2000, 14:S25-30.
28. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Journal of Affective Disorders 1998, 51:215-235.
29. Stein M.B., Schork N.J., Gelernter J. Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 2008, 33:312-319.
30. Swade C., Millne P., Coppen A. The effect of mitrazepam and other hypnotics on platelet 5-HT uptake. British Journal of Clinical Pharmacology 1981, 12:588-590.
31. Uhde T.W., Berrettini W.H., Roy-Byrne P.P., Boulenger J.P., Post R.M. Platelet [3H]imipramine binding in patients with panic disorder. Biological Psychiatry 1987, 22:52-58.
32. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in Neuropsychopharmacology and Biological Psychiatry 2003, 27:85-102.